<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The activated B-cell-like (ABC) subtype of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) remains the least curable form of this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> despite recent advances in therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Constitutive nuclear factor (NF)-κB and JAK kinase signalling promotes malignant cell survival in these <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, but the genetic basis for this signalling is incompletely understood </plain></SENT>
<SENT sid="2" pm="."><plain>Here we describe the dependence of <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCLs</z:e> on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling, and the discovery of highly recurrent oncogenic mutations affecting MYD88 in <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="40" ids="33697">RNA</z:chebi> interference screening revealed that MYD88 and the associated kinases IRAK1 and IRAK4 are essential for <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCL</z:e> survival </plain></SENT>
<SENT sid="4" pm="."><plain>High-throughput <z:chebi fb="40" ids="33697">RNA</z:chebi> resequencing uncovered MYD88 mutations in <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCL</z:e> lines </plain></SENT>
<SENT sid="5" pm="."><plain>Notably, 29% of <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> harboured the same amino acid substitution, L265P, in the MYD88 Toll/IL-1 receptor (TIR) domain at an evolutionarily invariant residue in its hydrophobic core </plain></SENT>
<SENT sid="6" pm="."><plain>This mutation was rare or absent in other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> subtypes and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, but was observed in 9% of mucosa-associated lymphoid tissue <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>At a lower frequency, additional mutations were observed in the MYD88 TIR domain, occurring in both the ABC and germinal centre B-cell-like (GCB) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> subtypes </plain></SENT>
<SENT sid="8" pm="."><plain>Survival of <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCL</z:e> cells bearing the L265P mutation was sustained by the mutant but not the <z:mp ids='MP_0002169'>wild-type</z:mp> MYD88 isoform, demonstrating that L265P is a gain-of-function driver mutation </plain></SENT>
<SENT sid="9" pm="."><plain>The L265P mutant promoted cell survival by spontaneously assembling a protein complex containing IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB signalling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and interferon-β </plain></SENT>
<SENT sid="10" pm="."><plain>Hence, the MYD88 signalling pathway is integral to the pathogenesis of <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCL</z:e>, supporting the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> bearing oncogenic MYD88 mutations </plain></SENT>
</text></document>